▼Naltrexone/bupropion for obesity
@article{2017NaltrexonebupropionFO, title={▼Naltrexone/bupropion for obesity}, author={}, journal={Drug and Therapeutics Bulletin}, year={2017}, volume={55}, pages={126 - 129} }
▼ Naltrexone/bupropion (Mysimba - Orexigen Therapeutics Ireland Limited) is a fixed-dose combination product for the treatment of adults who are obese or overweight with at least one weight-related comorbidity, as an adjunct to diet and lifestyle modifications. Originally licensed by the European Medicines Agency (EMA) in 2015, it has recently been launched in the UK. Here, we review the evidence for its efficacy and safety and consider its place in therapy.
Topics from this paper
References
SHOWING 1-10 OF 30 REFERENCES
Naltrexone + bupropion (Mysimba). Too risky for only modest weight loss.
- Medicine
- Prescrire international
- 2015
- 2
Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date
- Medicine
- Drug design, development and therapy
- 2014
- 53
- PDF
A Randomized, Phase 3 Trial of Naltrexone SR/Bupropion SR on Weight and Obesity-related Risk Factors (COR-II)
- Medicine
- Obesity
- 2013
- 314
The efficacy and safety of the naltrexone/bupropion combination for the treatment of obesity: an update
- Medicine
- Hormones
- 2015
- 11
- PDF
Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
- Medicine
- The Lancet
- 2010
- 527
Weight Loss With Naltrexone SR/Bupropion SR Combination Therapy as an Adjunct to Behavior Modification: The COR‐BMOD Trial
- Medicine
- Obesity
- 2011
- 332
- PDF